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CASE REPORTBilateral periorbital swelling as the initial presentation
of cutaneous lupus erythematosus
Valeria Makeeva, BS,a Lucia Seminario-Vidal, MD, PhD,b Kathleen Beckum, MD,c and Naveed Sami, MDc
Birmingham, Alabama and Tampa, FloridaFrom
De
th
Bir
Fund
Confl
Corre
EF
ua
72Key words: angioedema; lupus erythematosus; periorbital edema.Abbreviations used:
ANA: antinuclear antibody
BID: twice a day
CLE: cutaneous lupus erythematosus
DIL: drug-induced lupus
SLE: systemic lupus erythematosusINTRODUCTION
Cutaneous lupus erythematosus (CLE), defined as
isolated cutaneous lesions without significant sys-
temic involvement, has a reported incidence and
prevalence of 4.3 and 73.2 per 100,000, respectively.1
It occurs more commonly among women with a
reported age of onset between the second and fourth
decades of life.1 The 3 more common subtypes of
lupus are systemic lupus erythematosus (SLE), sub-
acute cutaneous lupus, and discoid lupus erythema-
tosus. A subset of patients shows atypical clinical
manifestations of CLE, which are more rare subtypes
and pose a diagnostic and therapeutic challenge.
Antimalarial drugs are considered the mainstay of
systemic therapy. Because it may take 2 to 3 months
to note some improvement,2 oral or topical steroids
are used in conjunction to facilitate response. We
report a patient with an atypical presentation of CLE
who also responded to hydroxychloroquine and
review similar cases in the literature.
CASE REPORT
A man in his 40s presented with persistent
periorbital swelling for 7 months. The swelling first
appeared 2 days after stripping floors during his
work. He denied any associated pruritus, oral
symptoms, facial pain, dyspnea, fever, weight
changes, myalgias, arthralgias, weakness, or fatigue.
He also denied coming into contact with any new
products on his face or any newmedications. He had
a history of asthma but no history of allergies or
photosensitivity. He also had eczema, hypertension,
and depression well controlled with triamcinolone
cream, amlodipine, and doxepin, respectively. He
used ibuprofen about 4 times a week for tensionthe University of Alabama School of Medicinea; the
partment of Dermatology, University of South Floridab; and
e Department of Dermatology, University of Alabama at
mingham.c
ing sources: None.
icts of interest: None declared.
spondence to: NaveedSami,MD,DepartmentofDermatology,
H 414, 1530 3rd Ave S, Birmingham, AL 35294. E-mail: nsami@
b.edu.headaches for several years without any adverse
reactions, but he stopped using it within days of
noticing the periorbital swelling. However, the
swelling did not improve. A few months after, at an
outside hospital, he was given a diagnosis of sinusitis
and treated with amoxicillin/clavulanate and sys-
temic steroids. Symptoms initially improved but
relapsed when prednisone was tapered to less than
20 mg.
After 7 months of having the above symptoms and
lack of improvement of the swelling, he presented to
our service. Review of systems yielded normal results
other than the indicated above. Physical examination
found edema and erythema of the right lower and
upper eyelids and on the left upper eyelid (Fig 1).
The following laboratory investigations were
within normal limits: complete blood count, com-
plete metabolic profile, C-reactive protein, creatine
kinase, IgE levels, C4, C1-INH, C1q, and total hemo-
lytic complement. Results for antinuclear antibody
(ANA), anti-Sj€ogren’s syndromeerelated antigen A
and antigen B, antineutrophil cytoplasmic antibody,
antimicrosomal antibody, antihistone antibody,
aldolase, anti-Jo1, and anti-Mi2 antibody were
normal. Anti-dsDNA level was quantified at 45 IU/
mL (nl\ 4 IU/mL), and anti-Smith level was 1 AI
(nl\ 1 AI).JAAD Case Reports 2016;2:72-6.
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Fig 1. Clinical presentation. Marked edema and erythema of the right and left eyelids, with
diminished palpebral aperture.
Fig 2. A, Superficial and deep lymphocytic infiltrate perivascular and periadnexal infiltrate.
B, Deep periadnexal lymphocytic infiltrate with increased dermal mucin. (Original magnifi-
cations: A, 340; B, 3100.)
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radiograph, and urinalysis were normal. A maxillo-
facial computed tomography scan found soft tissue
swelling in the right lacrimal fossa with no focal
abscess. Biopsy results of the right lower eyelid are
shown in Fig 2.
He was further evaluated by the rheumatology
department, and no systemic findings were noted.
Our patient’s clinical presentation and histopatho-
logic findings were consistent with a diagnosis of
tumid lupus, a rare variant of CLE. Therefore, he was
initially treated with oral prednisone (40 mg/d) and
hydroxychloroquine (400 mg/d). The prednisone
dose was tapered and discontinued over 2 months
with complete resolution of the periorbital edema.Our patient remains under control and without a
relapse of cutaneous disease or development of
systemic symptoms on hydroxychloroquine
400 mg/d at his 1-year follow-up.
DISCUSSION
Periorbital edema is a rare and nonspecific pre-
sentation for several conditions including SLE, der-
matomyositis, solid facial edema, drug reactions
(including drug-induced lupus [DIL]), infections,
angioedema, systemic contact dermatitis, superior
vena cava syndrome, hypersensitivity reactions,
sarcoidosis, and others.3 Laboratory, histopathology,
and imaging studies ruled out these diagnoses in our
patient.
Table I. Demographics and clinical data in 6 patients with periorbital edema as the sole manifestation of CLE
Age Gender/Race
Time to
Diagnosis Serology Diagnostic Criteria Histopathology Treatment Response
24 Female/Caucasian 3 y ANA Histopathologic findings Hyperkeratosis, diffuse
with hydropic
degeneration, and
superficial and deep
perivascular, and
periadnexal
lymphocytic infiltrate
Hydroxychloroquine,
400 mg/d, with oral
prednisone at 60 mg/d
Marked improvement
after 1 month of
therapy7
51 Female/Caucasian 2 y ANA1 at 1:140
Anti-Ro1
Anti-La
ANA level above
laboratory reference
range
Histopathologic findings
Direct
immunofluorescence
with granular deposits
of immunoreactants
Hyperkeratosis, diffuse
epidermal atrophy
with focal erosion and
focal vacuolization of
the basal cell layer,
infundibular follicular
epithelium with
occasional civatte
bodies, dermal edema,
and a moderately
dense, superficial and
deep perivascular and
focally perifollicular
lymphohistiocytic
infiltrate
Quinacrine, 100 mg/d Marked improvement
after 5 wk; however,
therapy was
discontinued because
of generalized drug
eruption. Edema and
erythema remained in
remission 10 months
after therapy
discontinued.8
45 Female/Caucasian 2 y ANA
Anti-Ro
Anti-La
Histopathologic findings
Direct
immunofluorescence
with globular deposits
of immunoreactants
Epidermal atrophy with
hydropic degeneration
and multiple
eosinophilic globules,
dermal perivascular
and periadnexal
lymphohistiocytic
infiltrate
Hydroxychloroquine,
200 mg/d, increased to
400 mg/d after 2 mo
and added oral
prednisone at 40 mg/d
Mild improvement with
200 mg/d
hydroxychloroquine.
Complete resolution
2 months after starting
400 mg/d
hydroxychloroquine 1
40 mg/d prednisone.8
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42 Male/African-American 2 y ANA
Anti-Ro
Histopathologic findings
Direct
immunofluorescence
with granular deposits
of immunoreactants
Hyperkeratosis with focal
areas of parakeratosis,
dense lymphocytic
infiltrate at the
dermoepidermal
interface and hair
follicles,
lymphohistiocytic
infiltrate in the
reticular dermis
Hydroxychloroquine,
200 mg/d
Complete resolution of
edema and marked
improvement in
violaceous
discoloration after
1 month of treatment.
Only faint
postinflammatory
hyperpigmentation
remained after
3 months.9
23 Male/Caucasian 1 y ANA
Anti-Ro
Histopathologic findings
Direct
immunofluorescence
with granular deposits
of immunoreactants
Hyperkeratosis, diffuse
with hydropic
degeneration, and
superficial and deep
perivascular,
periadnexal
lymphocytic infiltrate
Second biopsy 1 year
later: Normal
epidermis with dermal
fibrosis and presence
of interstitial mucin
Chloroquine, 150 mg/BID
after 2 months without
improvement oral
prednisolone was
added at 60 mg/d.
Mild improvement after
2 months of
chloroquine, 150 mg/
BID 1 prednisolone
60 mg/d. Recurrent
periorbital edema
1 year later treated
with chloroquine,
150 mg/BID for
6 months failed to
alleviate symptoms.10
36 Male/Caucasian 2 y ANA
Anti-Ro
Anti-dsDNA1
Photosensitive facial
erythema
Anti-dsDNA antibody
level above laboratory
reference range
Histopathologic findings
Direct
immunofluorescence
with granular deposits
of immunoreactants
Epidermal atrophy and
focal vacuolization of
the basal layer with
occasional
Civatte bodies, dermal
pigment incontinence,
and superficial
perivascular
lymphocyte infiltration
with a few plasma cells
Strong staining with
alcian blue indicated a
marked dermal mucin
deposition
Chloroquine, 150 mg/BID Marked improvement
after 3 months of
therapy with
regression of unilateral
proptosis10
BID, Twice a day.
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76 Makeeva et alOur patient did not have any other local or
systemic clinical features such as skin lesions (helio-
trope rash, Gottron’s sign, shawl sign) or musculo-
skeletal symptoms and signs of myopathy
characteristic of dermatomyositis. Additionally, our
patient failed to meet the criteria for SLE because of
lack of systemic findings including fatigue, arthritis,
or involvement of other systems (renal, pulmonary,
cardiac, hematologic, neuropsychiatric). A drug-
induced process including DIL was less likely, as
the patient was taking ibuprofen for several years
before the onset of the facial edema without any
adverse reactions, and this did not resolve with the
discontinuation of ibuprofen. DIL also is reported to
be less likely to have a cutaneous presentation.
There was also a notable absence of eosinophils on
the biopsy findings. Results of serologic studies for
dermatomyositis, SLE, and DIL were normal. A
maxillofacial computed tomography scan also did
not show any findings seen in chronic sinusitis.
Although eyelid edema is reported to have a
4.8% cumulative incidence in SLE,4 and a few cases
are reported in discoid lupus erythematosus and
lupus erythematosus profundus,5,6 periorbital
edema as the sole presenting manifestation of CLE
is extremely rare. Of note, our patient did not meet
criteria for SLE or other systemic rheumatologic
conditions. To our knowledge, only 6 similar cases
have been reported.7-10 A review of the data
regarding these patients is presented in Table I.
Both women and men were equally affected with
ages at diagnosis ranging from 23 to 51 years. All
cases required histopathologic analysis from peri-
orbital areas to confirm the diagnosis with biopsies
finding a combination of a variation of findings
including superficial and deep perivascular and
periadnexal lymphocytic infiltrate, marked intersti-
tial mucin deposition, and vacuolar alteration of
basal layers. The presence of the first 2 findings in
our patient’s biopsy along with a notable absence
of other features including eosinophils were more
consistent with a diagnosis of tumid lupus. All
previously reported cases experienced a delay todiagnosis between 1 and 3 years. Five of the 6
patients had negative results for ANA, similar to our
patient. The treatment of choice for the cases of CLE
with periorbital edema was antimalarial drugs with
or without systemic corticosteroids. All patients
experienced some improvement with this therapy.
Five patients reported marked improvement within
1 to 3 months of therapy, similar to our patient
(Table I), suggesting that antimalarial drugs are an
effective therapeutic option for these patients. We
recommend CLE be considered in the differential
diagnosis of patients with persistent periorbital
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